Unterweger Harald, Janko Christina, Schwarz Marc, Dézsi László, Urbanics Rudolf, Matuszak Jasmin, Őrfi Erik, Fülöp Tamás, Bäuerle Tobias, Szebeni János, Journé Clément, Boccaccini Aldo R, Alexiou Christoph, Lyer Stefan, Cicha Iwona
Cardiovascular Nanomedicine Unit, Section of Experimental Oncology und Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung-Professorship, ENT Department, University Hospital Erlangen, Friedrich-Alexander-Universitaet Erlangen-Nuernberg.
Preclinical Imaging Platform Erlangen (PIPE), Institute of Radiology, University Hospital Erlangen, Erlangen, Germany.
Int J Nanomedicine. 2017 Jul 24;12:5223-5238. doi: 10.2147/IJN.S138108. eCollection 2017.
Iron oxide-based contrast agents have been in clinical use for magnetic resonance imaging (MRI) of lymph nodes, liver, intestines, and the cardiovascular system. Superparamagnetic iron oxide nanoparticles (SPIONs) have high potential as a contrast agent for MRI, but no intravenous iron oxide-containing agents are currently approved for clinical imaging. The aim of our work was to analyze the hemocompatibility and immuno-safety of a new type of dextran-coated SPIONs (SPIONdex) and to characterize these nanoparticles with ultra-high-field MRI. Key parameters related to nanoparticle hemocompatibility and immuno-safety were investigated in vitro and ex vivo. To address concerns associated with hypersensitivity reactions to injectable nanoparticulate agents, we analyzed complement activation-related pseudoallergy (CARPA) upon intravenous administration of SPIONdex in a pig model. Furthermore, the size-tunability of SPIONdex and the effects of size reduction on their biocompatibility were investigated. In vitro, SPIONdex did not induce hemolysis, complement or platelet activation, plasma coagulation, or leukocyte procoagulant activity, and had no relevant effect on endothelial cell viability or endothelial-monocytic cell interactions. Furthermore, SPIONdex did not induce CARPA even upon intravenous administration of 5 mg Fe/kg in pigs. Upon SPIONdex administration in mice, decreased liver signal intensity was observed after 15 minutes and was still detectable 24 h later. In addition, by changing synthesis parameters, a reduction in particle size <30 nm was achieved, without affecting their hemo- and biocompatibility. Our findings suggest that due to their excellent biocompatibility, safety upon intravenous administration and size-tunability, SPIONdex particles may represent a suitable candidate for a new-generation MRI contrast agent.
基于氧化铁的造影剂已在临床上用于淋巴结、肝脏、肠道和心血管系统的磁共振成像(MRI)。超顺磁性氧化铁纳米颗粒(SPIONs)作为MRI造影剂具有很高的潜力,但目前尚无静脉注射含铁氧化物的制剂被批准用于临床成像。我们工作的目的是分析一种新型葡聚糖包被的SPIONs(SPIONdex)的血液相容性和免疫安全性,并用超高场MRI对这些纳米颗粒进行表征。在体外和离体条件下研究了与纳米颗粒血液相容性和免疫安全性相关的关键参数。为了解决与可注射纳米颗粒制剂过敏反应相关的问题,我们在猪模型中分析了静脉注射SPIONdex后的补体激活相关假过敏反应(CARPA)。此外,还研究了SPIONdex的尺寸可调性以及尺寸减小对其生物相容性的影响。在体外,SPIONdex不会诱导溶血、补体或血小板激活、血浆凝固或白细胞促凝活性,对内皮细胞活力或内皮-单核细胞相互作用也没有相关影响。此外,即使在猪体内静脉注射5mg Fe/kg的情况下,SPIONdex也不会诱导CARPA。在小鼠体内注射SPIONdex后,15分钟后观察到肝脏信号强度降低,24小时后仍可检测到。此外,通过改变合成参数,实现了粒径减小至<30nm,而不影响其血液和生物相容性。我们的研究结果表明,由于其优异的生物相容性、静脉注射安全性和尺寸可调性,SPIONdex颗粒可能是新一代MRI造影剂的合适候选者。